MELA News 0.54 Mela Sciences Inc (MELA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mela Sciences Inc (MELA) 0.54 $MELA

Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook as CFO
Business Wire - Wed Apr 09, 7:23AM CDT
MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind(R) system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, appointed veteran healthcare executive Robert W. Cook as Chief Financial Officer, filling the position which had been vacant since December 31, 2013. Mr. Cook brings over 20 years of experience in senior finance and management leadership roles in the healthcare and pharmaceutical industries, most recently as SVP and CFO of Immune Pharmaceuticals Inc. (NASDAQ OMX First North and OTCQX:IMNP), a developer of antibody therapeutics for cancer treatment, following its merger with EpiCept Corporation (Nasdaq OMX Stockholm and OTCQX:EPCT).

MELA Sciences Announces 2013 Fourth Quarter and Year-End Financial Results
Business Wire - Mon Mar 17, 3:00PM CDT
MELA Sciences, Inc. (NASDAQ:MELA), (the "Company", developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced financial results for the fourth quarter and year ended December 31, 2013.

MELA Sciences elects Samuel E. Navarro to board
M2 - Mon Mar 17, 5:16AM CDT
Optical diagnostic company MELA Sciences (NasdaqCM:MELA) revealed on Friday the addition of Samuel E. Navarro to its board of directors, increasing its members to eight.

Optical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, as Director
Business Wire - Fri Mar 14, 6:55AM CDT
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the appointment of veteran medical device investment banker Samuel E. Navarro to the Board of Directors. Mr. Navarro's appointment brings MELA's Board to eight members.

MELA Sciences, Inc. (MELA) Pioneering Earlier Detection of Melanoma Is Featured in Flaherty Financial News Newsletter #41
Marketwire - Tue Mar 11, 9:35AM CDT
Fine tuning the crusade by MELA Sciences, Inc. (NASDAQ: MELA) to identify deadly melanoma earlier is featured in the March 10, 2014 issue of Flaherty Financial News Newsletter. It follows up two previous articles written four years ago.

Dermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
Business Wire - Thu Mar 06, 8:36AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results on Monday, March 17, 2014, after the market's close. MELA Sciences President and CEO, Rose Crane will host a conference call that day at 4:30pm ET to review the results and provide general business update.

Rose Crane, CEO of Melanoma Diagnostics Provider, MELA Sciences, to Be Interviewed Live Today on Clear Channel Business Talk Radio DFW1190AM
Marketwire - Tue Feb 25, 10:04AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, announced that its CEO Rose Crane will be interviewed live today by host Michael Yorba on Clear Channel Business Talk Radio's The Traders Network. All interested investors and prospective customers across the US are encouraged to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.

Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension to Meet NASDAQ Minimum Bid Price
Business Wire - Mon Feb 24, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a 180-day grace period it has received from NASDAQ to fulfill the minimum $1.00 bid price requirement. The extension gives the Company until August 18, 2014 to regain compliance.

MELA Sciences Completes Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Wed Feb 05, 4:15PM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common stock. Net proceeds to the Company from this offering are approximately $11.5 million.

Kakamega Small-Scale Farmers Get Sh29m World Bank Boost
by Hilton Otenyo - All Africa Global Media - Tue Feb 04, 4:43AM CST
SMALL scale farmers in Kakamega county have received Sh29 million through a World Bank funded project to boost income and reduce poverty.

Melanoma Diagnostic Provider, MELA Sciences Provides Details of Recent $12.45 Million Private Placement
Business Wire - Mon Feb 03, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today filed a Form 8-K providing full details from its recent Private Placement. Following is the text of the details relating to the private placement that were provided in the Form 8-K.

CORRECTING and REPLACING Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 1:03PM CST
Second graph, second sentence of release should read ...13,297,297 shares of common stock at an exercise price of $0.74. (sted ...11,714,286 shares of common stock at an exercise price of $0.74.).

Melanoma Diagnostic Provider, MELA Sciences, to Raise $12.45 Million in Private Placement to Institutional Investors and MELA Sciences Directors
Business Wire - Fri Jan 31, 8:44AM CST
MELA Sciences, Inc. (NASDAQ: MELA), (the Company) developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced it has entered into definitive agreements with institutional investors and management for the private placement of $12.45 million of the Company's convertible preferred stock, common stock warrants and common stock. The investors in the transaction were funds managed by Sabby Management, LLC, which comprise the Company's largest existing beneficial shareholder, and Broadfin Capital, LLC. In conjunction with the financing, MELA Sciences' directors have agreed to purchase $150,000 in restricted common stock priced at $0.74 per share, yesterday's closing bid price for MELA's common stock.

Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding Melanoma Diagnosis at Most Treatable Stage
Business Wire - Thu Jan 30, 6:55AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind(R) workshop during the 10th Annual Maui Derm Conference in Hawaii. The conference seeks to increase physicians' knowledge of developments in medical and cosmetic dermatology.

Medical Diagnostic Developer MELA Sciences to Present at SeeThruEquity Microcap Conf. Feb. 6 in NYC and to Exhibit at Maui Dermatology Conf. Jan. 26-30
Business Wire - Mon Jan 27, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at the SeeThruEquity Winter Microcap Investor Conference on February 6, 2014 at 9:30 am ET in New York. Ms. Crane; Robert Coradini, Chairman; Mary Phellan, Controller; and Diana Garcia Redruello, head of the MelaFind Commercial Team will be available for one-on-one meetings that day.

MELA Sciences Announces the Results of its Third Clinical Advisory Meeting and the Four Clinical Posters Presented at the Winter Clinical Dermatology Conference
Business Wire - Wed Jan 22, 6:55AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third company-sponsored Clinical Advisory meeting hosted during the Winter Clinical Dermatology Conference in Hawaii where technical advancements of MelaFind(R) and future technology development opportunities were discussed and user's validated its clinical use. MELA Sciences also displayed four clinical posters presentations at the conference, which took place from January 17 - 22, 2014.

Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters at Winter Clinical Dermatology Conference - January 17 - 22
Business Wire - Thu Jan 16, 6:55AM CST
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind(R), an FDA-approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, will host its third company-sponsored Clinical Advisory meeting for select dermatologists and key opinion leaders in melanoma and provide recent clinical findings at the Winter Clinical Dermatology Conference being held January 17-22 at the Fairmont Orchid Hotel, Kona Coast, Hawaii.

MELA Sciences Appoints Healthcare Executive Jeff O'Donnell as Director and Streamlines Board to Support Refocused Go-to-Market Strategy
Business Wire - Thu Jan 02, 7:00AM CST
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind(R), an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced a realignment of its Board's composition and size to better support the Company's refocused go-to-market strategy for MelaFind. MELA also announced the resignation of Richard I. Steinhart, SVP Finance and Chief Financial Officer, effective December 31st. Mr. Steinhart has served as MELA's CFO since 2006. A search process has been initiated with an executive recruiter to secure a replacement. Rose Crane, MELA's CEO, will handle the CFO responsibilities on an interim basis with the assistance of the company's controller.

MELA Sciences Reports Positive Reception for its Optical Melanoma Diagnostic Device at Clinical Advisory Meeting and Mount Sinai Winter Dermatology Symposium
Business Wire - Mon Dec 09, 11:47AM CST
MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind(R), an FDA approved non-invasive optical device that assists dermatologists in the diagnosis of melanoma, received positive dermatologist feedback from its second Clinical Advisory Meeting held in conjunction with the 16th Annual Mount Sinai Winter Dermatology Symposium last week.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 81

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 178

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 135

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
AI Echo Study Sharpens a Difficult HFpEF Diagnosis

Updated Category News Views 88

A single echo clip may be doing more useful work than plenty of flashy healthcare AI demos. The November 2026 Journal of Cardiac Failure focus issue puts a hard number on that possibility: pairing an AI read of a routine echocardiogram clip with the H?FPEF clinical score identified 78% of patients with hemodynamically confirmed HFpEF, versus 48% with the score alone. That...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 95

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
Elisity’s Texas Water Pilot Puts IonQ’s Deal in View

Updated Category News Views 189

Water-system security is not a place for chest-thumping Elisity’s role in Texas Project Watershed 250 lands on a problem that is painfully concrete: water and wastewater utilities have to keep pumps, treatment systems and plant operations running while trying to close cybersecurity gaps. That is a tougher job than selling another dashboard to a corporate IT department....

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 156

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading

Top 5 Most Recently Viewed Articles

Orion180 Unveils Innovative Customizable Flood Insurance

Updated Category News Views 177

Orion180 Launches Customizable Residential Flood Insurance Orion180 is making waves in the insurance sector by introducing its latest offering: a Residential Private Flood Insurance product designed to meet a variety of homeowner needs. Based in Melbourne, this innovative insurance leader is set to change how we approach flood insurance with a product that emphasizes...

Continue Reading
DIFD AUTO Revolutionizes Global Car Buying with Crypto Payments

Updated Category News Views 306

Transforming the Car Buying Experience with Cryptocurrency Today, as the digital landscape continues to evolve, DIFD AUTO stands at the forefront of a revolutionary shift in how consumers purchase vehicles. As a leading platform for cryptocurrency-based car transactions, DIFD AUTO allows customers around the globe to purchase brand-new, certified cars using major...

Continue Reading
Curtiss-Wright Reports Impressive Q3 Results and Outlook Boost

Updated Category News Views 102

Curtiss-Wright's Positive Financial Performance Curtiss-Wright Corporation (NYSE: CW) is a well-known global company recognized for providing highly engineered products and services. Recently, the company reported noteworthy financial results for the third quarter. The sales surged nearly 10% year-over-year, coming close to $800 million, with exceptional growth especially...

Continue Reading
Darling Ingredients Reports Q3 2024 Results Amid Challenges

Updated Category News Views 312

Third Quarter 2024 Overview Darling Ingredients Inc. today reported net income of $16.9 million, or $0.11 per diluted share for the third quarter of 2024. This represents a significant decline compared to net income of $125.0 million, or $0.77 per diluted share, in the third quarter of 2023. The notable decrease in net income is attributed to lower fat prices and reduced...

Continue Reading
Investigation Launched for Investors of Spyre Therapeutics, Inc.

Updated Category News Views 127

Investigation Launched into Spyre Therapeutics, Inc. Pomerantz LLP has announced an investigation on behalf of investors of Spyre Therapeutics, Inc., known by its stock ticker, NASDAQ: SYRE. This inquiry stems from allegations that the company, along with some of its executives and board members, may have been involved in securities fraud or engaged in other unlawful...

Continue Reading